RecruitingNot ApplicableNCT07404527

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery

Usefulness of Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation and Complication Prediction in Oncological Patients Undergoing Colorectal Surgery


Sponsor

Institute of Oncology Ljubljana

Enrollment

60 participants

Start Date

Oct 24, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Sarcopenia is a complex syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength. In patients with cancer, sarcopenia is associated with poorer prognosis, increased treatment-related toxicity, higher postoperative complication rates, reduced response to therapy, and decreased quality of life. Importantly, sarcopenia may be present even in patients with preserved nutritional status or overweight. Patients with gastrointestinal cancers are at particularly high risk of developing sarcopenia, both as a consequence of the malignant disease itself and as a result of systemic anticancer treatment. Early identification of patients at risk is therefore essential in order to enable timely nutritional and supportive interventions. The aim of this study is to evaluate the proportion of patients with gastrointestinal cancer who screen positive for sarcopenia risk using the SARC-F questionnaire before the start of systemic treatment and during treatment. Patients with a positive screening result will be referred for further clinical nutritional assessment and managed according to a multidisciplinary approach.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a body composition measurement tool (bioelectrical impedance analysis, or BIA) to help doctors manage fluids given during surgery for head and neck cancer patients receiving chemotherapy and radiation. Better fluid management may reduce complications. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with head and neck cancer (confirmed by tissue biopsy) - You are scheduled to receive induction chemotherapy followed by chemoradiation with cetuximab (a targeted therapy) - You have adequate organ function as required by the study **You may NOT be eligible if...** - You have previously received chemotherapy or radiation for head and neck cancer - You have uncontrolled other medical conditions that would prevent treatment - You are allergic to cetuximab - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCetuximab (CRC)

Cetuximab is administered in combination with induction chemotherapy followed by concurrent chemoradiotherapy, according to the study protocol.


Locations(1)

Institute of Oncology Ljubljana

Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07404527


Related Trials